---
title: "UCLA Progressive Supranuclear Palsy"
id: "2373"
type: "study"
slug: "sa000017"
published_at: "2021-02-25T20:07:18+00:00"
modified_at: "2026-03-26T15:37:08+00:00"
url: "https://dss.niagads.org/studies/sa000017/"
markdown_url: "https://dss.niagads.org/studies/sa000017.md"
excerpt: "This study includes subjects with Progressive Supranuclear Palsy (PSP). Subjects were enrolled in the davenutide PSP Phase Trail 2/3. Additional subjects were clinically diagnosed PSP at the University of California, San Francisco Memory and Aging Center. Participants met the modified..."
---

## Description

This study includes subjects with Progressive Supranuclear Palsy (PSP). Subjects were enrolled in the davenutide PSP Phase Trail 2/3. Additional subjects were clinically diagnosed PSP at the University of California, San Francisco Memory and Aging Center.

Participants met the modified Neuroprotection and Natural History in Parkinson Plus Syndrome study criteria for PSP.

*See*[https://clinicaltrials.gov/ct2/show/NCT01110720](https://clinicaltrials.gov/ct2/show/NCT01110720)
*for comprehensive inclusion and exclusion criteria.*

Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13(7):676-685. doi:10.1016/S1474-4422(14)70088-2. PMID: [24873720](https://pubmed.ncbi.nlm.nih.gov/24873720/)

## PI

Daniel Geschwind, PhD  
 *University of California, Los Angeles*

Adam Boxer, PhD  
 *University of California, San Francisco*

## Associated Datasets

- [NG00067 - ADSP Umbrella](https://dss.niagads.org/datasets/ng00067/) This dataset includes sequencing data and harmonized phenotypes from cohorts sequenced by the Alzheimer’s Disease Sequencing Project and other AD and Related Dementia’s studies. Samples are processed using a common… [Learn more](https://dss.niagads.org/datasets/ng00067/)

## Associated Sample Sets

- [snd10017 - PSP-UCLA WGS](https://dss.niagads.org/sample-sets/snd10017/) PSP UCLA samples were whole-genome sequenced at Illumina/NYGC on the HiSeq2000/2500 machine. BAM files from hg37 build were sent to GCAD for processing on the VCPA1.1 pipeline. 408 samples passed… [Learn more](https://dss.niagads.org/sample-sets/snd10017/)

## Cohorts

- [Progressive Supranuclear Palsy at the University of California, Los Angeles (PSP UCLA)](https://dss.niagads.org/cohorts/progressive-supranuclear-palsy-at-the-university-of-california-los-angeles-psp-ucla/) This study includes subjects with Progressive Supranuclear Palsy (PSP). Subjects were enrolled in the davenutide PSP Phase Trail 2/3. Additional subjects were clinically diagnosed PSP at the University of California,… [Learn more](https://dss.niagads.org/cohorts/progressive-supranuclear-palsy-at-the-university-of-california-los-angeles-psp-ucla/)

## Grants

UG3NS104095

## Acknowledgement

### Acknowledgment statement for any data distributed by NIAGADS:

Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging.

### For investigators using UCLA Progressive Supranuclear Palsy data:

If data are used for a publication, “on behalf of the AL-108-231 investigators” should be included in the authorship list.

## Publications

- Boxer AL. **Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.***The Lancet. Neurology. 2014 Jul.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/24873720/)